Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 8

Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis

Authors Yawn BP, Li YF, Tian HJ, Zhang J, Arcona S, Kahler KH

Published Date June 2013 Volume 2013:8 Pages 295—304

DOI http://dx.doi.org/10.2147/COPD.S42366

Received 5 January 2013, Accepted 22 March 2013, Published 27 June 2013

Barbara P Yawn,1 Yunfeng Li,2 Haijun Tian,2 Jie Zhang,2 Steve Arcona,2 Kristijan H Kahler2

1Department of Research, Olmsted Medical Center, Rochester, MN, USA; 2Department of Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Background: The use of inhaled corticosteroids in patients with chronic obstructive pulmonary disease (COPD) has been associated with an increased risk of pneumonia in controlled clinical trials and case-control analyses.
Objective: Using claims databases as a research model of real-world diagnosis and treatment, to determine if the use and dose of inhaled corticosteroids (ICS) among patients with newly diagnosed COPD are associated with increased risk of pneumonia.
Patients and methods: This was a retrospective cohort analysis of patients diagnosed with COPD between January 01, 2006 and September 30, 2010, drawn from databases (years 2006–2010). Patients (aged ≥45 years) were followed until first pneumonia diagnosis, end of benefit enrollment, or December 31, 2010, whichever was earliest. A Cox proportional hazard model was used to assess the association of ICS use and risk of pneumonia, controlling for baseline characteristics. Daily ICS use was classified into low, medium, and high doses (1 µg–499 µg, 500 µg–999 µg, and ≥1000 µg fluticasone equivalents daily) and was modeled as a time-dependent variable.
Results: Among 135,445 qualifying patients with a total of 243,097 person-years, there were 1020 pneumonia incidences out of 5677 person-years on ICS (crude incidence rate, 0.180 per person-year), and 27,730 pneumonia incidences out of 237,420 person-years not on ICS (crude incidence rate, 0.117 per person-year). ICS use was associated with a dose-related increase in risk of pneumonia, with adjusted hazard ratios (versus no use; (95% confidence interval) of 1.38 (1.27–1.49) for low-dose users, 1.69 (1.52–1.88) for medium-dose users, and 2.57 (1.98–3.33) for high-dose users (P < 0.01 versus no use and between doses).
Conclusion: The use of ICS in newly diagnosed patients with COPD is potentially associated with a dose-related increase in the risk of pneumonia.

Keywords: COPD, ICS, LABA, pneumonia

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Protocol for the asthma tools study: a pragmatic practice-based research network trial

Yawn BP, Bertram S, Kurland M, Wollan P, Graham D, Littlefield D, Smail C, Pace W

Pragmatic and Observational Research 2013, 4:7-18

Published Date: 4 June 2013

Exacerbations in the pre- and post-COPD diagnosis periods

Yawn BP, Wollan P, Rank M

Pragmatic and Observational Research 2013, 4:1-6

Published Date: 2 May 2013

Automated patient and medication payment method for clinical trials

Yawn BP, Madison S, Bertram S, Pace WD, Fuhlbrigge A, Israel E, Littlefield D, Kurland M, Wechsler ME

Open Access Journal of Clinical Trials 2013, 5:23-31

Published Date: 29 January 2013

Introduction of Asthma APGAR tools improve asthma management in primary care practices

Barbara P Yawn, Susan Bertram, Peter Wollan

Journal of Asthma and Allergy 2008, 1:1-10

Published Date: 31 August 2008

Readers of this article also read:

Liposomes as nanomedical devices

Bozzuto G, Molinari A

International Journal of Nanomedicine 2015, 10:975-999

Published Date: 2 February 2015

Fluorescent magnetic iron oxide nanoparticles for cardiac precursor cell selection from stromal vascular fraction and optimization for magnetic resonance imaging

Verma VK, Kamaraju SR, Kancherla R, Kona LK, Beevi SS, Debnath T, Usha SP, Vadapalli R, Arbab AS, Chelluri LK

International Journal of Nanomedicine 2015, 10:711-726

Published Date: 20 January 2015

The safety and efficacy of aspirin intake in photoselective vaporization laser treatment of benign prostate hyperplasia

Shao IH, Hou CP, Chen SM, Chen CL, Lin YH, Chang PL, Tsui KH

Clinical Interventions in Aging 2013, 8:431-432

Published Date: 16 April 2013

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Corrigendum

Hong SH, Kim JE, Kim YK, Minai-Tehrani A, Shin JY, Kang B, Kim HJ, Cho CS, Chae C, Jiang HL, Cho MH

International Journal of Nanomedicine 2012, 7:3069-3070

Published Date: 20 June 2012

Corrigendum

Sailasuta N, Harris K, Tran T, Ross B

Neuropsychiatric Disease and Treatment 2011, 7:707-708

Published Date: 25 November 2011